But for the logic to hold true, does it not require that

New Post Public Reply Private Reply Replies (1) Message Board
ohm20 havasu78 #71930
641
Quote:
But for the logic to hold true, does it not require that CD12 report at least 50% mortality reduction?

No, the first thing te FDA will look at is ORR (overall response rate) or in this case the OS (overall survival rate or mortality rate) which shows what the level of clinical significance is. What level over placebo/ SOC the FDA is looking for we don't know exactly. With standard of care it may be as low as a 20% benefit.

Quote:
Many posters have offered statistical analysis here as to the mortality reduction which would be achieved for p<0.05.

At the interim, the mortality reduction for p<0.05 was around 50%.

At 390, the mortality reduction for p<0.05 was around 33%.


p value (probability value) just tells you whether the likelihood of a particular outcome is true. What is considered statistically significant is p =< .05. Which means there's a 5% or less chance that the outcome is wrong and a 95% chance that it's right. It does no good to have clinical significance if the results might be untrue.

The larger the patient population the more likely it is that the outcome is true. Where clinical significance comes into the picture is that the larger the percentage of people with a positive outcome the less patient population you need to prove a statistically significant probability value. With a fairly small population trial a statistically significant outcome will also show good clinical significance thus it's importance.

You could have an outlandishly large trial with 1 million patients and have a massively good statistical significance but clinical significance would be so small as to be useless. But that's one of the reasons they figure out the correct trial size beforehand.

Quote:
But since I am clueless on these statistics, I now believe that efficacy (in other words mortality reduction) is a variable component in the "power" function equation


The power function basically tells you what the odds are that if the trial was run again you'd come up with the same results.

To everyone - if I am incorrect in any of my explanations please feel free to correct me.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 14

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading

Top 5 Most Recently Viewed Articles

DoorLoop Achieves Prestigious Award for User Satisfaction

Updated Category News Views 227

DoorLoop Achieves Notable Recognition in Property Management Software Celebrated on Capterra's 2025 Shortlist with Outstanding Satisfaction Ratings DoorLoop, the innovative property management software designed for efficiency, has received the honor of being the highest-rated choice among property management software in the latest Capterra selection. This recognition from...

Continue Reading
The Surprising Rise of Robocalls: What We Can Do About It

Updated Category News Views 530

The Robocall Epidemic of 2025 In a startling revelation, U.S. consumers experienced over 4.3 billion robocalls just in July 2025. This staggering statistic, reported by YouMail's Robocall Index, shines a light on the growing nuisance that has plagued phone users for years. Interestingly, while July's figures remained consistent with the previous year, there has been a...

Continue Reading
Revolutionizing Telecommunications: The Launch of 5-Band RRU

Updated Category News Views 197

ZTE and MTN’s Groundbreaking Collaboration for Telecom Innovation ZTE Corporation and MTN have announced the successful commercial deployment of an innovative technology—the world's first 5-band Remote Radio Unit (RRU). This significant achievement highlights a new era in telecommunications, with implications that stretch beyond individual companies to impact the...

Continue Reading
Innovative Hydro Project Set to Transform Energy Landscape

Updated Category News Views 167

Introducing a Revolutionary Hydroelectric Project In a significant move towards advancing renewable energy, Current Hydro has announced the launch of its 28.5 MW Robert C. Byrd Locks and Dam Hydroelectric Project. This project will utilize the flows of the Ohio River, providing reliable and sustainable energy solutions while also focusing on environmental preservation and...

Continue Reading
Mercury Systems Secures Defense Contract to Enhance RF Solutions

Updated Category News Views 213

Mercury Systems Wins Key Defense Contract Mercury Systems, Inc. (NASDAQ: MRCY) is making headlines as it has been selected by the U.S. Department of Defense (DoD) for an important contract that seeks to bolster America’s defense supply chain. The focus centers around the development of a state-of-the-art RF signal conditioning multi-chip package (MCP), which is pivotal...

Continue Reading